Drug Database
HE

hepatitis A vaccine (Havisure)

✓ Approved

Indian Immunologicals · 疫苗 · 疫苗

什么是 hepatitis A vaccine?

hepatitis A vaccine 是一种疫苗,由Indian Immunologicals研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Havisure
公司Indian Immunologicals
药物类别疫苗, 大分子
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

hepatitis A vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresAntiviral prophylaxis✓ Approved

相关研究文献

PubMedBMC immunology2026-11-17

In Silico affinity profiling differentiates consensus vaccine sequences where genetic and structural similarity fail: a case study on HCV E2 genotypic and pan-genotypic antigens.

Mohabati Reyhaneh R, Teimoori-Toolabi Ladan L, Azadmanesh Kayhan K, Roohvand Farzin F et al.

The World Health Organization's goal to eradicate hepatitis C by 2030 remains unattainable without an effective vaccine. Consensus generation combined with layering has the potential to introduce vaccines against highly variable viruses like HCV. However, this approach yields numerous candidates that require in vivo testing. Profiling the affinity of these candidates to monoclonal antibodies via in silico methods can help reduce the number of candidates. In this study, we evaluated the differentiating power of in silico affinity profiling on two previously reported genotypic consensus sequences (NOTC1 and NOTC2) and two newly generated pan-genotypic sequences (L1-CON and L2-CON), each derived using distinct consensus generation algorithms. Structural models of these sequences were generated via homology modelling and simulated within a canonical ensemble. The resulting average structures were then used as inputs for antigen-antibody docking studies against all reported antibody structures known to bind to each epitope in the HCV E2 protein. Docking results for epitope II revealed lower binding energies for NOTC1 compared to NOTC2 (p = 0279) and J-2a (p = 0.0132) consistent with their reported in vivo performance. This discrimination was not reproduced in genetic distance from the common ancestor of Genotype 1 and also structural similarity between protein models and crystalographed antigen. Notably, neither sequence nor structural similarity correlated with the docking outcomes, highlighting the predictive value of the proposed affinity profiling pipeline as an initial assessment tool for vaccine candidates.

PMID 43040467
阅读全文 →
PubMedVirology journal2026-11-17

Identification of coding-region mutations associated with attenuation of an Egyptian duck hepatitis A virus type 1 isolate following serial egg passage.

Hisham Islam I, Ali Ahmed A, El-Abideen Mohamed A Zain MAZ, Adel Amany A et al.

Duck hepatitis A virus type 1 (DHAV-1) causes a highly contagious disease with high mortality in young ducklings. Although serial passage in embryonated eggs is widely used for virus adaptation and attenuation, the molecular changes associated with DHAV-1 attenuation remain poorly understood. A virulent Egyptian DHAV-1 isolate was serially passaged 84 times in embryonated chicken eggs. The parental virus (P0) and the passage-84 virus (P84) were subsequently compared for pathogenicity in Pekin ducklings, replication in embryonated chicken eggs, and whole-genome sequence analysis. The parental virus caused 100% mortality within 72 h, whereas the P84 virus caused neither clinical signs nor mortality and replicated to higher titers in embryonated chicken eggs, demonstrating complete attenuation. Whole-genome sequencing identified 11 nucleotide substitutions, including four non-synonymous mutations in the VP3, 2A, and 2C proteins. Serial passage in embryonated chicken eggs resulted in complete attenuation of DHAV-1 after 84 passages, despite the accumulation of four amino acid substitutions. These findings demonstrate that profound phenotypic attenuation can arise with minimal genomic evolution and identify candidate mutations in VP3, 2A, and particularly 2C for future reverse-genetics studies and rational live vaccine development.

PMID 43040369
阅读全文 →
PubMedHepatology forum2026-11-17

Reverse hepatitis B seroconversion without immunosuppression: A case report and literature review.

Zhu Kai K, Wu Eric E, Tam Benson B, Yoshida Eric M EM et al.

We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.

PMID 43042239
阅读全文 →
PubMedBMC gastroenterology2026-11-17

Incidence of liver cancer and decompensated cirrhosis amongst hepatitis B and C notifications in Tasmania- a data linkage study.

Ibegu Maria M, Le Tuan Nguyen Anh A, Stephens Nicola N, de Graaff Barbara B

Liver cancer is a leading cause of cancer-related death globally, with both incidence and mortality rates rising sharply in Australia over the past three decades. Chronic hepatitis B and C are major contributors to liver cancer, and its common precursor, decompensated cirrhosis. This study assessed the incidence of liver cancer and decompensated cirrhosis among individuals with hepatitis B and C in Tasmania. A retrospective population-based study was conducted using linked datasets. The cohort included all individuals with a notification for hepatitis B and/or C in Tasmania from 1995 to 2022. Cases were linked to the Tasmanian Cancer Register and admitted patient data from Tasmanian public hospitals. Incidence rates per 1,000 person-years were calculated for liver cancer and decompensated cirrhosis. Between 1995 and 2022, 1,280 hepatitis B (55.5% male) and 6,658 hepatitis C (64.3% male) notifications were recorded in Tasmania. A total of 145 liver cancer registrations and 270 decompensated cirrhosis-related admissions were observed. Among individuals with hepatitis B, the incidence rates were 5.39 per 1,000 person-years for liver cancer and 3.00 per 1,000 person-years for decompensated cirrhosis. Among those with hepatitis C, corresponding rates were 2.33 and 5.02 per 1,000 person-years. While the number of liver-related outcomes was relatively low and did not support more detailed analyses, a trend towards higher incidence rates was observed over the study period. These findings highlight the burden of liver-related complications among individuals with hepatitis B and C in Tasmania. Liver cancer was more common among those with hepatitis B, while decompensated cirrhosis was more frequent among those with hepatitis C. Observed trends should be interpreted cautiously, as they may reflect changes in population characteristics, surveillance, and healthcare engagement. Strengthening testing, treatment uptake, and long-term monitoring is essential to reduce the burden of advanced liver disease in this regional setting.

PMID 43040487
阅读全文 →
PubMedBMC public health2026-11-17

Post-introduction evaluation of COVID-19 vaccine deployment in Ghana: lessons learnt to inform future new vaccine introductions and strengthen public health readiness, 2023.

Amponsa-Achiano Kwame K, Shen Angela K AK, Baiden Laryea Eunice E, Carlton Julie Garon JG et al.

On March 2nd, 2021, Ghana, the first country to receive vaccines from the COVAX facility, began its COVID-19 vaccination using a complex multi-phased approach, to reach target populations. We evaluated the vaccine deployment to document best practices challenges and lessons for future new vaccine introductions and public health emergency readiness. We conducted a mixed methods post-introduction evaluation, purposively sampling 36 facilities from 12 districts in six regions. Adapting the World Health Organization's COVID-19 Post-Introduction Evaluation tool, we conducted a cross-sectional survey using a structured questionnaire, reviewed programme records, observed practices, and interviewed purposively selected health workers, immunization managers and partners who supported vaccine deployment. We performed summary descriptive statistics on quantitative data, thematic analysis on qualitative data, and triangulated the results. As of March 2023, more than 70% of the target population (15 years and older) had received at least one dose, while more than 50% had completed the primary series. Vaccine deployment was built on the existing immunisation programme and functional coordinating bodies. Cold chain capacity was revamped with ultra-low-temperature freezers, while 33.3% of surveyed districts adjusted waste disposal systems to accommodate COVID-19 vaccine introduction. Door-to-door delivery and demand generation through varied risk communication and community engagement strategies improved vaccine access. Electronic data platforms were established, surge capacity improved, and healthcare and community workers were trained. Initial unpredictable vaccine supplies limited vaccination efforts. Changing vaccine information affected health workers' ability to engage communities with up-to-date guidance. While vaccine safety monitoring systems were in place, reporting knowledge varied among health workers, and 36% of surveyed facilities had ever documented and reported COVID-19 vaccine-related adverse events following immunisation. Challenges with electronic data systems limited timely access to and use of granular service-delivery data for decision-making. Ghana leveraged existing immunisation and emergency-response systems to make substantial progress in COVID-19 vaccine deployment. Coordination, cold chain expansion, flexible service delivery, demand generation and workforce mobilisation supported implementation. Irregular vaccine supply, data system challenges, variable adverse event reporting, waste management pressure and misinformation challenged deployment. These findings provide lessons for adult immunisation, life-course vaccination and future public health emergency readiness.

PMID 43040294
阅读全文 →
PubMedFrontiers in veterinary science2026-11-17

Ginsenoside Rg1 as an adjuvant enhances immunity in chickens immunized with the H9N2 avian influenza inactivated vaccine.

Zhang Pengju P, Wang Hongtao H, Li Mengman M, Lyu Xuefeng X et al.

To investigate the potential use of Ginsenoside Rg1 as an adjuvant for the H9N2 avian influenza vaccine, the study examined Rg1's immunomodulatory effects on an inactivated H9N2 vaccine. A total of 150 one-day-old non-immunized Arbor Acres (AA) chickens were randomly assigned to three groups (n = 50 each): one receiving the H9N2 inactivated vaccine, another receiving Rg1 alongside the vaccine, and a control group treated with PBS. Each group underwent three immunization sessions spaced 2 weeks apart. Serum samples were taken to measure IgG antibody levels and hemagglutination inhibition (HI) titers. Lymphocyte proliferation was assessed using cell counting kits-8 and flow cytometry. The levels of serum cytokines, including Interferon-γ (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-4, and IL-6, were quantified via ELISA. Fourteen days post-final immunization, the chickens were challenged with the H9N2 strain, and viral titers in the lungs and kidneys were measured. Findings indicated that the group receiving Rg1 with the vaccine exhibited a notable increase in specific IgG and HI titers. Furthermore, this group showed enhanced T cell proliferation and elevated cytokine production, thereby bolstering cellular immunity. Importantly, the immune protection results revealed that the combination of Rg1 and the vaccine significantly improved the chickens' protection against viral strains, leading to a marked reduction in viral shedding. These findings imply that Rg1 may enhance the immune response and protective efficacy of the H9N2 inactivated vaccine, positioning it as a promising new adjuvant for H9N2 vaccination.

PMID 43041234
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多hepatitis A vaccine